Indication
For the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
Medicine details
- Medicine name:
- zanubrutinib (Brukinsa)
- SMC ID:
- SMC2452
- Pharmaceutical company
- BeiGene UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 02 May 2022